Human HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Monomer Protein
Catalog No: MAGEA3-HP003
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
Product overview
Recombinant Human MAGE-A3(HLA-A*24:02) Protein is expressed from HEK293 with His tag and Avi tag at the C-terminus. It contains Gly25-Thr305(HLA-A*24:02), Ile21-Met119(B2M) and IMPKAGLLI peptide (accession: AAA59600.1(HLA-A*24:02) & P61769(B2M) &IMPKAGLLI).
Product Details
- Molecular Aliases
- Melanoma-associated antigen 3; MZ2-D; MZ2D; MZ2-D; CT1.3; MAGE-3
- Protein Length
- Gly25-Thr305
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 50.20 kDa. Due to glycosylation, the protein migrates to 55-60 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Monomer is greater than 95% as determined by SEC-HPLC.
Background
Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa.
References
- Khalvandi A, Abolhasani M, Madjd Z, Shekarabi M, Kourosh-Arami M, Mohsenzadegan M. Nuclear overexpression levels of MAGE-A3 predict poor prognosis in patients with prostate cancer. APMIS. 2021 Jun;129(6):291-303. doi: 10.1111/apm.13132. Epub 2021 Apr 13. PMID: 33743542.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.